- Home
- BBIO vs CYTK Comparison
BBIO vs CYTK Comparison
Compare BBIO & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BBIO
- CYTK
- Stock Information
- Founded
- BBIO 2015
- CYTK 1997
- Country
- BBIO United States
- CYTK United States
- Employees
- BBIO N/A
- CYTK N/A
- Industry
- BBIO Biotechnology: Pharmaceutical Preparations
- CYTK Biotechnology: Pharmaceutical Preparations
- Sector
- BBIO Health Care
- CYTK Health Care
- Exchange
- BBIO Nasdaq
- CYTK Nasdaq
- Market Cap
- BBIO 6.7B
- CYTK 5.6B
- IPO Year
- BBIO 2019
- CYTK 2004
- Fundamental
- Price
- BBIO $33.02
- CYTK $37.50
- Analyst Decision
- BBIO Strong Buy
- CYTK Strong Buy
- Analyst Count
- BBIO 12
- CYTK 17
- Target Price
- BBIO $52.64
- CYTK $82.00
- AVG Volume (30 Days)
- BBIO 2.7M
- CYTK 1.6M
- Earning Date
- BBIO 05-01-2025
- CYTK 05-07-2025
- Dividend Yield
- BBIO N/A
- CYTK N/A
- EPS Growth
- BBIO N/A
- CYTK N/A
- EPS
- BBIO N/A
- CYTK N/A
- Revenue
- BBIO $221,902,000.00
- CYTK $18,474,000.00
- Revenue This Year
- BBIO $12.42
- CYTK $55.82
- Revenue Next Year
- BBIO $123.19
- CYTK $683.10
- P/E Ratio
- BBIO N/A
- CYTK N/A
- Revenue Growth
- BBIO 2285.27
- CYTK 145.34
- 52 Week Low
- BBIO $21.62
- CYTK $37.46
- 52 Week High
- BBIO $39.47
- CYTK $75.71
- Technical
- Relative Strength Index (RSI)
- BBIO 45.09
- CYTK 30.18
- Support Level
- BBIO $35.77
- CYTK $42.66
- Resistance Level
- BBIO $37.06
- CYTK $48.43
- Average True Range (ATR)
- BBIO 1.46
- CYTK 2.19
- MACD
- BBIO -0.01
- CYTK -0.50
- Stochastic Oscillator
- BBIO 23.60
- CYTK 0.36
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
About CYTK Cytokinetics Incorporated
Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.